At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 231 enrolled
Drug / intervention
Nafithromycin 800 mg 3 days +2 moredrug
Likely dose
Nafithromycin 800 mg 3 daysfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
In Brief
A Phase 2 clinical trial evaluating Nafithromycin 800 mg 3 days, Nafithromycin 800 mg 5 days, and 1 other intervention for Community-Acquired Bacterial Pneumonia (CABP). Completed, enrolled 231 participants across 6 sites.
Detailed Summary
Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsACM
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionJul 2017
Study CompletionJul 2017
TodayJul 2026
First PostedSep 16, 2016
Enrollment StartNov 18, 2016
Primary CompletionJul 1, 2017
Study CompletionJul 8, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.8 years ago
Interventions
Nafithromycin 800 mg 3 daysdrug
Nafithromycin 800 mg 5 daysdrug
Moxifloxacin 400 mgdrug